Quarterly report [Sections 13 or 15(d)]

Selected Balance Sheet Data

v3.25.1
Selected Balance Sheet Data
9 Months Ended
Mar. 31, 2025
Notes to Financial Statements  
Selected Balance Sheet Data

Note 3. Selected Balance Sheet Data:

Inventories:

Inventories consist of (in thousands):

    

March 31, 

June 30, 

    

2025

    

2024

Raw materials

$

83,453

$

79,377

Finished goods(1)

 

113,310

 

106,072

Inventories, net

$

196,763

$

185,449

(1) Finished goods inventory of $5,680 and $5,718 is included within Other long-term assets in the respective March 31, 2025 and June 30, 2024. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the Condensed Consolidated Balance Sheet date.

Property and Equipment:

Property and equipment consist of (in thousands):

    

March 31, 

June 30, 

    

2025

    

2024

Land

$

8,105

$

8,150

Buildings and improvements

 

249,896

 

243,863

Machinery and equipment

240,948

215,948

Construction in progress

 

31,819

 

39,749

Property and equipment, cost

 

530,768

 

507,710

Accumulated depreciation and amortization

 

(278,791)

 

(256,556)

Property and equipment, net

$

251,977

$

251,154

Intangible Assets:

Intangible assets consist of (in thousands):

March 31, 

June 30, 

2025

2024

Developed technology

$

677,236

$

675,674

Tradenames

 

151,378

 

151,561

Customer relationships

 

211,480

 

211,276

Patents

 

4,829

 

4,343

Other intangibles

 

7,162

 

12,006

Definite-lived intangible assets

 

1,052,085

 

1,054,860

Accumulated amortization

 

(608,386)

 

(547,779)

Total intangible assets, net

$

443,699

$

507,081

Changes to the carrying amount of net intangible assets for the period ended March 31, 2025 consist of (in thousands):

    

March 31, 

2025

Beginning balance

$

507,081

Other additions

 

364

Amortization expense

 

(57,714)

Restructuring impairment

(7,050)

Currency translation

1,018

Ending balance

$

443,699

The estimated future amortization expense for intangible assets as of March 31, 2025 is as follows (in thousands):

Remainder 2025

    

$

18,889

2026

 

72,497

2027

 

62,326

2028

 

58,616

2029

 

46,049

Thereafter

 

185,322

Total

$

443,699

Goodwill:

Changes to the carrying amount of goodwill for the period ended March 31, 2025 consist of (in thousands):

    

    

Diagnostics and

    

Protein Sciences

 Spatial Biology

Total

June 30, 2024

$

423,449

$

549,214

$

972,663

Currency translation

 

(2,334)

(1,717)

(4,051)

March 31, 2025

$

421,115

$

547,497

$

968,612

We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a qualitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2024. No indicators of impairment were identified as part of our assessment.

Other Assets:

Other assets consist of (in thousands):

    

March 31, 

June 30,

    

2025

2024

Equity method investment in Wilson Wolf

$

239,515

$

242,337

Derivative instruments

0

9,813

Long-term inventory

5,680

5,718

Investment in Spear Bio

15,000

Other

 

8,792

 

6,397

Other assets

$

268,987

$

264,265